LTR PHARMA LIMITED — Director's Dealing 2025

Nov 19, 2025

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity LTR Pharma Limited ABN 42 103 087 449

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Maja McGuire
Date of last notice	9 December 2024

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [408 x 294] intentionally omitted <==

----- Start of picture text ----- Direct or indirect interest IndirectNature of indirect interest Maja Mcguire <Scaraf A/C>(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.Date of change 19 November 2025No. of securities held prior to change 100,000 Unlisted Options exercisable at $2.52per option expiring 2 December 2028235,492 Fully Paid Ordinary Shares500,000 Unlisted Options exercisable at $0.22per option expiring 31 October 2028Class Unlisted OptionsNumber acquired 1,000,000Number disposed Not applicableValue/Consideration Nil considerationNote: If consideration is non-cash, provide details and estimatedvaluation----- End of picture text -----

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after changeNature of changeExample: on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participation in buy-back

100,000 Unlisted Options exercisable at $2.52per option expiring 2 December 20281,000,000 Unlisted Options exercisable at$0.5075 per option expiring 24 October 2029235,492 Fully Paid Ordinary Shares500,000 Unlisted Options exercisable at $0.22per option expiring 31 October 2028Issue of 1,000,000 Unlisted Options under theEmployee Incentive Plan as approved byshareholders at the Company’s 2025 AnnualGeneral Meeting (Resolution 9)

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [408 x 304] intentionally omitted <==

----- Start of picture text ----- Detail of contract Not applicableNature of interest Not applicableName of registered holder Not applicable(if issued securities)Date of change Not applicableNo. and class of securities to which interest Not applicablerelated prior to changeNote: Details are only required for a contract in relation to which theinterest has changedInterest acquired Not applicableInterest disposed Not applicableValue/Consideration Not applicableNote: If consideration is non-cash, provide details and an estimatedvaluationInterest after change Not applicable----- End of picture text -----

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?

If prior written clearance was provided, on what date was this provided?

Not applicable

Not applicable

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3